Holen Sie sich die Stockscreener-App
5.91
3.90%
-0.24
Handel nachbörslich:
29.72
23.81
+402.88%
Schlusskurs vom Vortag:
$6.15
Offen:
$6.14
24-Stunden-Volumen:
1.27M
Relative Volume:
0.89
Marktkapitalisierung:
$433.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.17M
KGV:
-3.2888
EPS:
-1.797
Netto-Cashflow:
$-39.99M
1W Leistung:
+32.81%
1M Leistung:
+58.87%
6M Leistung:
+271.70%
1J Leistung:
+2,074%
1-Tages-Spanne:
$5.82
$6.45
1-Wochen-Bereich:
$5.80
$7.51
52-Wochen-Spanne:
$0.243
$7.51
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs GOODO, PSNYW, SHMD, DWLD, QQQE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
19.87 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.86 | 378.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
6.31 | 383.66M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
44.12 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.94 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Fortgesetzt | Leerink Partners | Outperform |
| 2025-12-22 | Eingeleitet | Jefferies | Buy |
| 2025-11-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
RLMD Stock Surges 42% in a Week: Here's What You Should Know - TradingView
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data - Sahm
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - Investing News Network
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - Investing News Network
Relmada Therapeutics (RLMD) Stock Surges as Bladder Cancer Trial Shows 76% Response Rate - MEXC
Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement - Quiver Quantitative
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Mizuho reiterates Relmada stock rating on bladder cancer trial data - Investing.com
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3 - Bez Kabli
Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal - Tokenist
Why Is Relmada Therapeutics Stock Soaring Monday? - Bitget
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data - parameter.io
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data and $160M Financing - MoneyCheck
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - Asianet Newsable
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data" - StreetInsider
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Is Relmada Therapeutics Stock (RLMD) Up Today? - TipRanks
Relmada Therapeutics (RLMD) Secures $160M through PIPE Financing - GuruFocus
Relmada Therapeutics secures $160M in PIPE financing - Investing.com
Relmada Therapeutics prices 29.47M shares at $4.75 in private placement - TipRanks
Relmada Therapeutics (RLMD) Reports Promising 12-Month Data for NDV-01 Trial - GuruFocus
Relmada Therapeutics Raises Capital, Highlights Promising NDV-01 Data - TipRanks
Relmada Therapeutics recently announced positive data for its investigational drug NDV-01 in high-risk non-muscle invasive bladder cancer. - Bitget
Relmada Therapeutics stock surges 25% on bladder cancer data By Investing.com - Investing.com Australia
Relmada Therapeutics stock surges 25% on bladder cancer data - Investing.com
Relmada Therapeutics Raises $160 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Experimental bladder cancer therapy NDV-01 achieves 76% 1-year complete response - Stock Titan
Relmada Therapeutics recently disclosed that its phase 3 second-line study targeting BCG non-responsive patient groups is expected to yield preliminary 3-month efficacy data by the end of 2026. - Bitget
Relmada Therapeutics (NASDAQ:RLMD) Rating Increased to Strong-Buy at Lucid Cap Mkts - MarketBeat
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):